Takeda Halts Development Of Actos Combination Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese drug maker will focus on other projects in diabetes after ending fixed-dose combination of Actos with its angiotensin receptor blocker azilsartan.